Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoMed TherapeuticsGDTC +12.50%27 EBITDA Margin % is -897.71% as of Dec. 2025. GuruFocus rates GDTC with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, CytoMed Therapeutics ranks worse than 80% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CytoMed Therapeutics EBITDA Margin % Related Terms
CytoMed Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CytoMed Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GDTC vs LEXX, INAB, TRAW: EBITDA Margin % Comparison
For the Biotechnology subindustry, CytoMed Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics (GDTC) has a EBITDA Margin % of -897.71% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CytoMed Therapeutics and its competitors. According to the industry distribution chart, CytoMed Therapeutics ranks #752 out of 940 companies in the Biotechnology industry, placing it in the top 80%.
Is CytoMed Therapeutics' EBITDA Margin % too high?
CytoMed Therapeutics' current EBITDA Margin % is -897.71%. Based on the distribution chart, CytoMed Therapeutics ranks #752 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CytoMed Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' EBITDA Margin % compare to LEXX and INAB?
According to the Biotechnology industry distribution chart, CytoMed Therapeutics ranks #752 out of 940 companies for EBITDA Margin %. This places CytoMed Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CytoMed Therapeutics and its competitors. CytoMed Therapeutics's current EBITDA Margin % is -897.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (GDTC) has a current EBITDA Margin % of -897.71%. The current EBITDA Margin % is -897.71%. CytoMed Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CytoMed Therapeutics (GDTC), the current EBITDA Margin % is -897.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
27GF Score
Get the complete analysis for GDTC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDTC has been successfully added to your 
